

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

**Initial preparation date:** 05.01.2019 Page 1 of 11

**Revision date:** 01.25.2024

#### CARFLEXIN 20mg/50mg/100mg TABLETS

#### **SECTION 1: Identification**

#### Product identifier

Product name: CARFLEXIN 20mg/50mg/100mg TABLETS

**Synonyms:** CARFLEXIN TABLETS (PLAIN)

#### Recommended use of the product and restriction on use

Relevant identified uses: Veterinary use: Analgesic; Anti-inflammatory

Uses advised against: Not for human use

Reasons why uses advised against: Veterinary product.

#### Manufacturer or supplier details

# Supplier:

**Australia** 

Dechra Veterinary Products (Australia) Pty Ltd 2 Cal Close Somersby, NSW 2250 1300 015 825 info.au@dechra.com http://www.dechra.com.au/

#### **Emergency telephone number:**

# **Australia**

Poisons Information Centre 13 11 26 (24 hours, 7 days a week)

# **SECTION 2: Hazard(s) identification**

# Classification in accordance with Australian Work Health and Safety Regulations and the GHS Revision 7:

Acute toxicity (oral), category 4

## **Label elements**

#### **Hazard pictograms:**



Signal Word: Warning

#### **Hazard statements:**

H302 Harmful if swallowed

#### **Precautionary statements:**

P102 Keep out of reach of children

P264 Wash hands thoroughly for 15 minutes after handling.

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 2 of 11

**Revision date: 01.25.2024** 

# CARFLEXIN 20mg/50mg/100mg TABLETS

P270 Do not eat, drink or smoke when using this product

P301+P312 IF SWALLOWED: Call a POISON CENTER or doctor if you feel unwell.

P330 Rinse mouth

P501 Dispose of contents and container in accordance with local regulations.

#### Hazards not otherwise classified:

None

#### **SECTION 3: Composition and information on ingredients**

| Identification         | Name                       | Weight % |
|------------------------|----------------------------|----------|
| CAS number: 10039-26-6 | Lactose                    | 30-60    |
| CAS number: 53716-49-7 | Carprofen                  | 15-30    |
| CAS number: 9004-34-6  | Microcrystalline cellulose | 10-30    |
| CAS number: 9005-25-8  | Starch pregelatinized      | 10-30    |
| CAS number: 9003-39-8  | Crospovidone               | <10      |
| CAS number: 14807-96-6 | Talc purified              | <10      |
| CAS number: 557-04-0   | Magnesium distearate       | <1       |

#### **Additional Information:**

The specific chemical identity and/or exact percentage (concentration) of composition has been withheld as a trade secret in accordance with the Australian Work Health and Safety Regulations 2021.

#### **SECTION 4: First aid measures**

#### **Description of first aid measures**

#### **General notes:**

Show this Safety Data Sheet to the doctor in attendance. Take precautions to ensure your own safety before attempting rescue. Wear appropriate safety eyewear, gloves, protective clothing and respiratory protection to prevent exposure. See Section 8 of this SDS for personal protective equipment recommendations. Do not use the mouth to mouth method if victim has ingested or inhaled the product. Give artificial respiration with the aid of a pocket mask equipped with a one-way valve or other proper device.

#### After inhalation:

If inhaled, remove person to fresh air and place in a position comfortable for breathing. Keep person at rest. If breathing is difficult, administer oxygen. If breathing has stopped, provide artificial respiration. If symptoms develop or persist, seek medical advice/attention.

## After skin contact:

Remove contaminated clothing and shoes. Rinse skin with copious amounts of water [shower] for several

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 3 of 11

**Revision date: 01.25.2024** 

## CARFLEXIN 20mg/50mg/100mg TABLETS

minutes. Launder contaminated clothing before reuse. If symptoms develop or persist, seek medical advice/attention.

# After eye contact:

Rinse eyes with plenty of water for several minutes. Remove contact lenses, if present and easy to do so. Protect unexposed eye. If symptoms develop or persist, seek medical advice/attention.

#### After swallowing:

If swallowed, DO NOT induce vomiting unless told to do so by a physician or poison control center. Rinse mouth with water. Never give anything by mouth to an unconscious person. If spontaneous vomiting occurs, place on the left side with head down to prevent aspiration of liquid into the lungs. If symptoms develop or persist, seek medical advice/attention.

## Most important symptoms and effects, both acute and delayed

## Acute symptoms and effects:

Acute oral exposure may lead to dizziness, drowsiness, headache, breathing difficulties, nausea, vomiting, abdominal pain, and lowering of consciousness. Adverse effects are dependent on exposure (dose, concentration, contact time).

## **Delayed symptoms and effects:**

Symptoms of exposure may be delayed.

## Immediate medical attention and special treatment

#### **Specific treatment:**

Not determined or not applicable.

#### Notes for the doctor:

Treat symptomatically.

## **SECTION 5: Fire fighting measures**

# **Extinguishing media**

## Suitable extinguishing media:

Water mist/fog, carbon dioxide, dry chemical or alcohol resistant foam.

#### Unsuitable extinguishing media:

Do not use water jet.

#### Specific hazards during fire-fighting:

Thermal decomposition may produce irritating/toxic fumes/gases.

#### Special protective equipment for firefighters:

Fire-fighters should wear appropriate protective equipment and self-contained breathing apparatus (SCBA) with a full-face piece operated in positive pressure mode.

## Special precautions:

Avoid contact with skin, eyes, hair and clothing. Do not breathe fumes/gas/mists/aerosols/vapors/dusts. Move containers from fire area if safe to do so. Use water spray/fog for cooling fire exposed containers. Avoid unnecessary run-off of extinguishing media which may cause pollution.

#### **SECTION 6: Accidental release measures**

## Personal precautions, protective equipment and emergency procedures:

Evacuate unnecessary personnel. Ventilate area. Extinguish any sources of ignition. Wear recommended personal protective equipment (see Section 8). Do not get on skin, eyes or on clothing. Avoid breathing mist,

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 4 of 11

**Revision date: 01.25.2024** 

## CARFLEXIN 20mg/50mg/100mg TABLETS

vapor, dust, fume and spray. Do not walk through spilled material. Wash thoroughly after handling. Remove contaminated clothing and launder before reuse.

#### **Environmental precautions:**

Prevent further leakage or spillage if safe to do so. Prevent from reaching drains, sewers and waterways. Discharge into the environment must be avoided.

## Methods and material for containment and cleaning up:

Harmful if swallowed. Do not touch damaged containers or spilled material unless wearing appropriate personal protective clothing. Avoid breathing dust, mist, fumes, vapors or spray. Stop leak if you can do it without risk. Contain and collect spillage and place in suitable container for future disposal. Dispose of in accordance with all applicable regulations (see Section 13).

#### Reference to other sections:

For personal protective equipment see Section 8. For disposal see Section 13.

# **SECTION 7: Handling and storage precautions**

#### Precautions for safe handling:

Use appropriate personal protective equipment (see Section 8). Use only with adequate ventilation. Avoid breathing mist/vapor/spray/dust. Do not eat, drink, smoke, or use personal products when handling chemical substances. Avoid contact with skin, eyes and clothing. Wash affected areas thoroughly after handling. Keep away from incompatible materials (See Section 10). Keep containers tightly closed when not in use.

#### Conditions for safe storage, including any incompatibilities:

Storage areas and containers should be clearly marked for drug holding, protected from light, freezing or physical damage and tightly sealed when not in use. Keep out of reach of children. Store below 30°C. Store in cool, dry, well-ventilated location out of direct sunlight. Keep away from food and beverages. Protect from freezing and physical damage. Store away from heat, open flames and other sources of ignition. Keep container tightly sealed. Store away from incompatible materials (See Section 10).

## SECTION 8: Exposure controls and personal protection

Only those substances with limit values have been included below.

#### Occupational Exposure limit values:

| Country (Legal<br>Basis) | Substance                  | Identifier | Permissible concentration  |
|--------------------------|----------------------------|------------|--|
| Australia                | Microcrystalline cellulose | 9004-34-6  | 8-Hour TWA: 10 mg/m <sup>3</sup>   |
|                          | Starch pregelatinized      | 9005-25-8  | 8-Hour TWA: 10 mg/m³<br>(containing no Asbestos and<br><1% Crystalline silica<br>inhalable dust) |
|                          | Magnesium distearate       | 557-04-0   | TWA: 10 mg/m³ (No Asbestos and <1% Crystalline silica inhalable dust (as Stearates))             |
|                          | Talc purified              | 14807-96-6 | TWA: 2.5 mg/m³   |
|                          | Talc purified              | 14807-96-6 | TWA: 10 mg/m³ (nuisance dusts, inhalable)  |

## **Biological limit values:**

No biological exposure limits noted for the ingredient(s).

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 5 of 11

**Revision date: 01.25.2024** 

## CARFLEXIN 20mg/50mg/100mg TABLETS

#### Information on monitoring procedures:

Not determined or not applicable.

## **Appropriate engineering controls:**

Emergency eye wash stations and safety showers should be available in the immediate vicinity of use or handling. Provide adequate ventilation to maintain the airborne concentrations of vapor, mists, and/or dusts below the applicable workplace exposure limits, while observing recognized national standards (or equivalent).

## Personal protection equipment

## Eye and face protection:

Safety glasses or goggles. Use eye protection equipment that has been tested and approved by recognized national standards (or equivalent).

## Skin and body protection:

Chemical resistant, impervious gloves approved by the appropriate standards. Gloves must be inspected prior to use. Avoid skin contact with used gloves. Appropriate techniques should be used to remove used gloves and contaminated clothing. Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. Ensure that all personal protective equipment is approved by recognized national standards (or equivalent).

## **Respiratory protection:**

If engineering controls do not maintain airborne concentrations below the applicable workplace exposure limits, or to an acceptable level (if exposure limits have not been established), a respirator approved by recognized national standards (or equivalent) must be worn.

#### General hygienic measures:

When handling chemical products, do not eat, drink or smoke. Wash hands after handling, before breaks, and at the end of the workday. Avoid contact with skin, eyes and clothing. Wash contaminated clothing before reuse. Perform routine housekeeping.

#### **SECTION 9: Physical and chemical properties**

#### Information on basic physical and chemical properties

| Physical state                     | White solid                      |
|------------------------------------|----------------------------------|
| Colour                             | Not applicable                   |
| Odour                              | Not determined or not available. |
| рН                                 | Not determined or not available. |
| Melting point/freezing point       | Not determined or not available. |
| Initial boiling point/range        | Not determined or not available. |
| Flash point (closed cup)           | Not determined or not available. |
| Flammability (solid, gas)          | Not determined or not available. |
| Lower flammability/explosive limit | Not determined or not available. |
| Upper flammability/explosive limit | Not determined or not available. |
| Vapor pressure                     | Not determined or not available. |
| Relative density                   | Not determined or not available. |
| Relative vapor density             | Not determined or not available. |
| Density                            | Not determined or not available. |

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 6 of 11

**Revision date: 01.25.2024** 

# CARFLEXIN 20mg/50mg/100mg TABLETS

| Partition coefficient (n-octanol/water) | Not determined or not available. |
|---|----------------------------------|
| Auto/Self-ignition temperature          | Not determined or not available. |
| Decomposition temperature               | Not determined or not available. |
| Kinematic viscosity                     | Not determined or not available. |
| Particle characteristics                | Not determined or not available. |
| Solubilities                            | Soluble in water                 |

# **SECTION 10: Stability and reactivity**

#### Reactivity:

Not reactive under recommended handling and storage conditions.

#### Chemical stability:

Stable under recommended handling and storage conditions.

# Possibility of hazardous reactions:

Hazardous reactions are not anticipated under recommended conditions of handling and storage.

#### **Conditions to avoid:**

Extreme heat, open flames, hot surfaces, sparks, ignition sources and incompatible materials.

## **Incompatible materials:**

None known.

#### Hazardous decomposition products:

Under normal conditions of storage and use, hazardous decomposition products should not be produced.

# **SECTION 11: Hazard information**

#### **Acute toxicity**

#### **Assessment:**

Harmful if swallowed.

Product data: No data available.

**Substance data:** 

| Name                       | Route      | Result                                  |
|----------------------------|------------|---|
| Carprofen                  | oral       | LD50 Rat: 74 mg/kg                      |
| Microcrystalline cellulose | dermal     | LD50 Rabbit: > 2000 mg/kg               |
|                            | inhalation | LC50 Rat: > 5.8 mg/L (4 hr [dust/mist]) |
|                            | oral       | LD50 Rat: > 5000 mg/kg                  |
| Talc purified              | oral       | LD50 Rat: > 5000 mg/kg                  |
|                            | dermal     | LD50 Rat: > 2000 mg/kg                  |
|                            | inhalation | LC50 Rat: > 2.1 mg/L (4hr [aerosol])    |
| Magnesium distearate       | dermal     | LD50 Rat: >2000 mg/kg                   |

#### Skin corrosion/irritation

Assessment: Based on available data, the classification criteria are not met.

**Product data:**No data available.

Substance data: No data available.

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 7 of 11

**Revision date: 01.25.2024** 

## CARFLEXIN 20mg/50mg/100mg TABLETS

#### Serious eye damage/irritation

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:**No data available.

Substance data: No data available.

## Respiratory or skin sensitization

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:**No data available.

**Substance data:** No data available.

# Carcinogenicity

**Assessment:** Based on available data, the classification criteria are not met.

Product data: No data available.

#### Substance data:

| Name          | Species | Result  |
|---------------|---------|---|
| Talc purified |         | Talc containing asbestos is carcinogenic to humans. |

## International Agency for Research on Cancer (IARC):

| Name          | Classification |
|---------------|----------------|
| Crospovidone  | Group 3        |
| Talc purified | Group 3        |

National Toxicology Program (NTP): None of the ingredients are listed.

#### Germ cell mutagenicity

Assessment: Based on available data, the classification criteria are not met.

**Product data:**No data available.

Substance data: No data available.

#### Reproductive toxicity

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:**No data available.

Substance data: No data available.

## Specific target organ toxicity (single exposure)

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:**No data available.

Substance data: No data available.

# Specific target organ toxicity (repeated exposure)

**Assessment:** Based on available data, the classification criteria are not met.

**Product data:**No data available.

Substance data: No data available.

#### Aspiration toxicity

**Assessment:** Based on available data, the classification criteria are not met.

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 8 of 11

**Revision date: 01.25.2024** 

# CARFLEXIN 20mg/50mg/100mg TABLETS

**Product data:**No data available.

Substance data: No data available.

## Information on likely routes of exposure:

Oral ingestion.

# Symptoms related to the physical, chemical and toxicological characteristics:

See section 4 of this SDS.

#### Other information:

No data available.

# **SECTION 12: Ecological information**

# Acute (short-term) toxicity

Assessment: Based on available data, the classification criteria are not met.

Product data: No data available.

#### Substance data:

| Name          | Result  |
|---------------|---|
| Talc purified | Fish LC50 Freshwater fish: 89581 mg/L (96 hr [QSAR])                  |
|               | Aquatic Plants EC50 Green algae: 7203 mg/L (96 hr [QSAR])             |
|               | Aquatic Invertebrates EC50 Daphnid species: 36812 mg/L (48 hr [QSAR]) |

# Chronic (long-term) toxicity

**Assessment:** Based on available data, the classification criteria are not met.

Product data: No data available.

#### Substance data:

| Name          | Result  |
|---------------|---|
| Talc purified | Fish NOEC Freshwater fish: 5980 mg/L (30 d [QSAR])                  |
|               | Aquatic Invertebrates NOEC Daphnid species: 1460 mg/L (30 d [QSAR]) |
|               | Aquatic Plants NOEC Green algae: 918 mg/L (30 d [QSAR])             |

# Persistence and degradability

Product data: No data available.

#### **Substance data:**

| Name          | Result   |
|---------------|--|
| Talc purified | Persistence assessment based on biodegradability is not applicable for |
|               | inorganic substances such as this one.                                 |

# **Bioaccumulative potential**

Product data: No data available.

#### **Substance data:**

| Name          | Result   |
|---------------|--|
| Talc purified | Substance is not expected to bioaccumulate (calculated BCF: 3.162 L/kg). |

# Mobility in soil

Product data: No data available.

Substance data:

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 9 of 11

**Revision date: 01.25.2024** 

# CARFLEXIN 20mg/50mg/100mg TABLETS

| Name | Result  |
|------|---|
|      | Substance is mobile in soil with low potential for adsorption to soil and sediment (calculated Koc: 31.82). |

#### Results of PBT and vPvB assessment

#### **Product data:**

**PBT assessment:** This product does not contain any substances that are assessed to be a PBT. **vPvB assessment:** This product does not contain any substances that are assessed to be a vPvB.

#### **Substance data:**

# PBT assessment:

| · ·              | The substance is inorganic, and as such the criteria for PBT are not applicable.  |  |
|------------------|---|--|
| vPvB assessment: |   |  |
| · ·              | The substance is inorganic, and as such the criteria for vPvB are not applicable. |  |

Other adverse effects: No data available.

# **SECTION 13: Disposal considerations**

#### **Disposal methods:**

It is the responsibility of the waste generator to properly characterize all waste materials according to applicable regulatory entities

# Contaminated packages:

Not determined or not applicable.

# **SECTION 14: Transport information**

#### Australian Dangerous Goods (ADG)

| UN number                     | Not regulated |
|-------------------------------|---------------|
| UN proper shipping name       | Not regulated |
| UN transport hazard class(es) | None          |
| Packing group                 | None          |
| Environmental hazards         | None          |
| Special precautions for user  | None          |

# **International Maritime Dangerous Goods (IMDG)**

| UN number                     | Not regulated |
|-------------------------------|---------------|
| UN proper shipping name       | Not regulated |
| UN transport hazard class(es) | None          |
| Packing group                 | None          |
| Environmental hazards         | None          |
| Special precautions for user  | None          |

International Air Transport Association Dangerous Goods Regulations (IATA-DGR)

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 10 of 11

**Revision date: 01.25.2024** 

# CARFLEXIN 20mg/50mg/100mg TABLETS

| UN number                     | Not regulated |
|-------------------------------|---------------|
| UN proper shipping name       | Not regulated |
| UN transport hazard class(es) | None          |
| Packing group                 | None          |
| Environmental hazards         | None          |
| Special precautions for user  | None          |

| Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code |      |  |
|---|------|--|
| Bulk Name   | None |  |
| Ship type   | None |  |
| Pollution category  | None |  |

# **SECTION 15: Regulatory information**

# **Australia regulations**

# **Australian Inventory of Chemical Substances (AICS):**

| 53716-49-7 | Carprofen                  | Not           |
|------------|----------------------------|---------------|
|            |                            | Listed        |
| 10039-26-6 | Lactose                    | Not<br>Listed |
| 9004-34-6  | Microcrystalline cellulose | Listed        |
| 9005-25-8  | Starch pregelatinized      | Listed        |
| 9003-39-8  | Crospovidone               | Listed        |
| 557-04-0   | Magnesium distearate       | Listed        |
| 14807-96-6 | Talc purified              | Listed        |

# Standard for the Uniform Scheduling of Medicines and Poisons (SUSMP):

| Ingredient Name            | CAS        | Schedules      |
|----------------------------|------------|----------------|
| Carprofen                  | 53716-49-7 | 4              |
| Lactose                    | 10039-26-6 | Not Applicable |
| Microcrystalline cellulose | 9004-34-6  | Not Applicable |
| Starch pregelatinized      | 9005-25-8  | Not Applicable |
| Crospovidone               | 9003-39-8  | Not Applicable |
| Magnesium distearate       | 557-04-0   | Not Applicable |
| Talc purified              | 14807-96-6 | Not Applicable |

#### **Additional information:**

Poison schedule: Classified as Schedule 4 (S4) Standard for the Uniform Scheduling of Medicines and

Poisons (SUSMP)

APVMA Numbers: 63924 (20mg); 63922 (50mg); 63923 (100mg)

# **SECTION 16: Other information**

**Abbreviations and Acronyms: None** 

According to Australian Work Health and Safety Regulations 2021 and the GHS Revision 7

Initial preparation date: 05.01.2019 Page 11 of 11

**Revision date: 01.25.2024** 

# CARFLEXIN 20mg/50mg/100mg TABLETS

#### Disclaimer:

This SDS was authored in accordance with the Australian Work Health and Safety Regulations 2021 and the GHS Revision 7 and supplemented by the Australian Code of Practice on the Preparation of Safety Data Sheets for Hazardous Chemicals. The information provided in this SDS is correct, to the best of our knowledge, based on information available. The information given is designed only as a guidance for safe handling, use, storage, transportation and disposal and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials, unless specified in the text. The responsibility to provide a safe workplace remains with the user.

Initial preparation date: 05.01.2019

**Revision date:** 01.25.2024

**Revision Notes:** 

| Revision Date | Notes     |
|---------------|-----------|
| 2024-01-25    | Version 2 |

**End of Safety Data Sheet**